ストックスクリーナーアプリを入手
7.47
1.42%
0.08
前日終値:
$7.39
開ける：
$7.47
24時間の取引高:
4,188
Relative Volume:
0.06
時価総額：
$214.84M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.07%
1か月 パフォーマンス:
+43.03%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.45
$7.50
1週間の範囲:
$6.53
$7.51
52週間の値動き範囲:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
名前
Insight Molecular Diagnostics Inc
セクター
電話
949-409-7600
住所
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
IMDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
7.495 | 211.83M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
621.46 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.06 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
721.24 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.89 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
245.59 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
Insight Molecular Diagnostics Inc (IMDX) 最新ニュース
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx By Investing.com - Investing.com South Africa
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com Canada
Insight Molecular Diagnostics Inc. Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - marketscreener.com
Insight Molecular Diagnostics (IMDX) Nears Key FDA Submission Mi - GuruFocus
IMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - marketscreener.com
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - GlobeNewswire
iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard - MSN
Prostate Cancer Diagnostics Market Size Report, 2026 – 2035 - Global Market Insights Inc.
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - FinancialContent
KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform - The Newark Advocate
Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183m - Yahoo Finance
Molecular Cytogenetics Market Analysis Reveals Growth - openPR.com
Insight Molecular (IMDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Insight Molecular Diagnostics (FRA:7OC0) EV-to-OCF : -5.98 (As of Dec. 24, 2025) - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11% - simplywall.st
Why Insight Molecular Diagnostics Inc. (7OC0) stock attracts HNW investorsQuarterly Risk Review & Verified Short-Term Trading Plans - DonanımHaber
Biosensors Market Size, Share & Analysis | Growth Report [2032] - Fortune Business Insights
United States Molecular Diagnostics Market Trends & Summary - vocal.media
Is Insight Molecular Diagnostics Inc. (7OC0) stock suitable for passive index fundsJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Is Insight Molecular Diagnostics Inc. (7OC0) stock a safe buy pre earningsMarket Sentiment Review & Safe Capital Preservation Plans - Newser
Will Insight Molecular Diagnostics Inc. (7OC0) stock sustain dividend payoutsOptions Play & Real-Time Volume Trigger Notifications - Newser
Why global investors buy Insight Molecular Diagnostics Inc. (7OC0) stock2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
Why Insight Molecular Diagnostics Inc. (7OC0) stock stays resilientMarket Movers & Real-Time Buy Zone Alerts - Newser
How Insight Molecular Diagnostics Inc. (7OC0) stock compares with market leaders2025 Big Picture & High Conviction Buy Zone Picks - Newser
Pullback Watch: Can Insight Molecular Diagnostics Inc 7OC0 stock beat analyst consensusEarnings Recap Report & Verified Momentum Stock Ideas - moha.gov.vn
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate - Yahoo Finance
Specialty Enzymes Market will reach $12.71 Billion by 2033Strategic Revenue Insights - industrytoday.co.uk
Diagnostic Specialty Enzymes Market will reach US$2.49 Billion by 2033Strategic Revenue Insights - industrytoday.co.uk
Tissue Diagnostic Market will reach US$25.07 Billion by 2033Strategic Revenue Insights - industrytoday.co.uk
Transplant Monitoring Kits Market Size, Share | CAGR Of 4.6% - Market.us
Insight Molecular Diagnostics (IMDX) Price Target Increased by 29.23% to 7.14 - MSN
Will Insight Molecular Diagnostics Inc. (7OC0) stock remain on Wall Street radarJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock gain from green policiesQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Can Insight Molecular Diagnostics Inc. (7OC0) stock sustain institutional flowsJuly 2025 Breakouts & Verified High Yield Trade Plans - newser.com
Published on: 2025-11-19 17:04:49 - newser.com
Published on: 2025-11-19 13:52:26 - newser.com
Published on: 2025-11-19 13:17:14 - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock worth holding before Fed meetingMarket Volume Report & Capital Efficient Trade Techniques - newser.com
Insight Molecular Diagnostics Inc (IMDX) 財務データ
Insight Molecular Diagnostics Inc (IMDX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.56%
0.67%
大文字化:
|
ボリューム (24 時間):